Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options
Theresa Mallick-Searle,Jeremy Adler
DOI: https://doi.org/10.2147/jpr.s442595
IF: 2.8319
2024-03-13
Journal of Pain Research
Abstract:Theresa Mallick-Searle, 1, &ast Jeremy A Adler 2, &ast 1 Division Pain Medicine, Stanford Health Care, Redwood City, CA, USA; 2 Pacific Pain Medicine Consultants, Encinitas, CA, USA &astThese authors contributed equally to this work Correspondence: Jeremy A Adler, Pacific Pain Medicine Consultants, 477 N El Camino Real, Suite B301, Encinitas, CA, 92024, USA, Tel +1 760 753 1104, Fax +1 760 943 6494, Email Painful diabetic peripheral neuropathy (DPN) is a highly prevalent and disabling complication of diabetes that is often misdiagnosed and undertreated. The management of painful DPN involves treating its underlying cause via lifestyle modifications and intensive glucose control, targeting its pathogenesis, and providing symptomatic pain relief, thereby improving patient function and health-related quality of life. Four pharmacologic options are currently approved by the US Food and Drug Administration (FDA) to treat painful DPN. These include three oral medications (duloxetine, pregabalin, and tapentadol extended release) and one topical agent (capsaicin 8% topical system). More recently, the FDA approved several spinal cord stimulation (SCS) devices to treat refractory painful DPN. Although not FDA-approved specifically to treat painful DPN, tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, gabapentinoids, and sodium channel blockers are common first-line oral options in clinical practice. Other strategies may be used as part of individualized comprehensive pain management plans. This article provides an overview of the most recent US guidelines for managing painful DPN, with a focus on the two most recently approved treatment options (SCS and capsaicin 8% topical system), as well as evidence for using FDA-approved and guideline-supported drugs and devices. Also discussed are unmet needs for this patient population, and evidence for potential future treatments for painful DPN, including drugs with novel mechanisms of action, electrical stimulation devices, and nutraceuticals. Keywords: neuropathic, pain, painful diabetic peripheral neuropathy, treatment, guidelines, diabetic nerve pain Diabetic peripheral neuropathy (DPN) is among the most common complications of type 1 diabetes (T1D) and type 2 diabetes (T2D) 1,2 in the United States (US), approximately 37 million individuals have diabetes, predominantly (90–95%) T2D, with an additional 96 million adults having prediabetes. 3 An estimated 50% of diabetic patients and 10‒30% of prediabetic patients will develop neuropathy. 4,5 Neuropathy is accompanied by pain in approximately 20–40% of afflicted patients, many of whom continue to have unresolved pain even with treatment. 2,6–10 Diabetic neuropathic pain is associated with a high prevalence of anxiety, depression and sleep disorders which can amplify the disease burden and increase the complexity of management, 11 particularly with respect to treatment selection and potential for drug–drug interactions (DDIs) and adverse drug reactions (ADRs) in the presence of polypharmacy. Major risk factors for DPN are hyperglycemia in T1D and metabolic syndrome in T2D. 12 Although glycemic control helps to prevent DPN in patients with T1D, it provides modest or no benefits in preventing DPN in patients with T2D, likely due to the presence of co-morbidities. 12 The development of painful DPN has been associated with numerous factors including poorly controlled glucose levels, worsening glucose tolerance, T2D (relative to T1D), insulin resistance, tobacco smoking, excessive alcohol consumption, advanced age and duration of diabetes, diabetic vessel disease, abdominal obesity, hypertension, elevated triglyceride levels, and low high-density lipoprotein levels. 8,10 Typically, DPN presents initially as distal neuropathy without pain in the feet, followed by a gradual and symmetric progression of predominantly sensory symptoms including, paradoxically, numbness with exquisite sensitivity, allodynia and hyperalgesia. 6,13,14 Neuropathy symptoms arise from damage to the peripheral sensory nerves, accompanied by a gradual decrease in epidermal nerve fiber density, resulting in a worsening of sensory loss and an increase in responsiveness to painful stimuli. 15 The pathophysiological processes involved in the development of painful DPN are complex and appear to involve sustained hyperglycemia, dyslipidemia, and altered insulin signaling. 8,16 These lead to several possible pathological alterations (eg, DNA and macrophage activation damage, endoplasmic reticulum stress, mitochondrial dysfunction, neurodegeneration, and loss of neurotrophic signaling) in neurons and other cells critical to normal functioning. D -Abstract Truncated-
clinical neurology